Cardiogen from Super Human Peptides UK is a highly targeted, synthetic tetrapeptide (sequence: Ala-Glu-Asp-Arg). It belongs to the specialized class of short peptide bioregulators originally developed by the St. Petersburg Institute of Bioregulation and Gerontology.
In laboratory research, Cardiogen serves as a premier model for investigating cardiovascular regeneration and the reversal of myocardial aging. Researchers utilize this peptide to study its profound, epigenetic effect on heart tissue. Unlike systemic growth factors, Cardiogen specifically targets myocardial cells to stimulate the proliferation of young cardiomyocytes while simultaneously inhibiting the excessive growth of fibroblasts (the cells responsible for creating stiff, fibrotic scar tissue).
Produced under GMP-compliant conditions and verified for 99% purity or higher, Cardiogen is an essential tool for advanced in-vitro and in-vivo research into heart failure, ischemic injury recovery, and age-related cardiac hypertrophy.
- —Cardiac Bioregulator: A short, 4-amino-acid peptide that acts as an epigenetic switch specifically for myocardial tissue.
- —Fibrosis Inhibition: Actively suppresses runaway fibroblast proliferation, preventing the formation of stiff scar tissue in the heart.
- —Cardiomyocyte Proliferation: Stimulates the division and maturation of heart muscle cells to replace damaged tissue.
- —Anti-Apoptotic: Studied for its ability to down-regulate p53 protein expression, saving cardiac cells from programmed cell death.
- —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —Quality Standard: GMP / ISO certified manufacturing.
- —Myocardial Infarction Models: Preclinical investigation into the rapid recovery of heart muscle and the prevention of necrotic tissue spread following severe blood flow restriction.
- —Cellular Apoptosis: Studying the intracellular signaling pathways that down-regulate p53 expression, protecting cultured cardiomyocytes from oxidative stress.
- —Fibroblast Modulation: Researching the delicate balance between necessary collagen production and pathological fibrosis (stiffening) in the aging heart.
- —Gene Expression: Investigating the peptide's ability to enter the nucleus and interact directly with the DNA promoter regions of specific cardiac-related genes.
- —Endurance and Hemodynamics: Evaluating the secondary physical outcomes of restored cardiac output, including enhanced exercise capacity and normalized blood pressure in aged animal models.
Cardiogen was synthesized as part of the groundbreaking bioregulator research led by Dr. Vladimir Khavinson. Khavinson’s team discovered that as organisms age, the production of naturally occurring short peptides drops dramatically, leading to the epigenetic silencing of critical repair genes and subsequent organ decay.
Laboratory studies utilizing Cardiogen have demonstrated unprecedented tissue-specific recovery. In foundational in-vitro studies, the application of Cardiogen to cultured myocardial tissue from aged subjects resulted in a massive resurgence of cell division. Furthermore, in animal models of induced acute myocardial infarction, subjects administered Cardiogen exhibited significantly smaller lesion sizes and dramatically less fibrotic scarring compared to control groups.
Because it treats the root epigenetic cause of cardiac aging rather than simply masking symptoms (like traditional beta-blockers or ACE inhibitors), it remains a primary focus in advanced gerontological and cardiovascular medicine.
- 1.Khavinson, V.H. et al., "Peptide bioregulators: A new class of geroprotectors," Annals of the New York Academy of Sciences, 2002.
- 2.Chalisova, N.I. et al., "The effect of the amino acid peptide cardiogen on the development of myocardial tissue culture from young and old rats," Advances in Gerontology, 2009.
- 3.Lezhava, T. et al., "Epigenetic regulation of gene expression by peptide bioregulators," Biogerontology, 2006.
- 4.Khavinson, V. et al., "Peptides promote longevity," Current Aging Science, 2013.
